BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30982572)

  • 21. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.
    Sluiter NR; Rovers KP; Salhi Y; Vlek SL; Coupé VMH; Verheul HMW; Kazemier G; de Hingh IHJT; Tuynman JB
    Ann Surg Oncol; 2018 Aug; 25(8):2347-2356. PubMed ID: 29855834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prior Surgical Score: An Analysis of the Prognostic Significance of an Initial Nondefinitive Surgical Intervention in Patients With Peritoneal Carcinomatosis of a Colorectal Origin Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy.
    Paul BK; Ihemelandu C; Sugarbaker PH
    Dis Colon Rectum; 2018 Mar; 61(3):347-354. PubMed ID: 29420428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
    Cashin PH; Graf W; Nygren P; Mahteme H
    Eur J Surg Oncol; 2012 Jun; 38(6):509-15. PubMed ID: 22475555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External validation of prognostic scores and comparison of predictive accuracy for patients with colorectal cancer with peritoneal metastases considered for cytoreductive surgery and intraperitoneal chemotherapy.
    Kozman MA; Fisher OM; Liauw W; Morris DL; Cashin PH
    J Surg Oncol; 2023 Dec; 128(7):1150-1159. PubMed ID: 37602499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis.
    Trilling B; Cotte E; Vaudoyer D; Isaac S; Piaton E; Maurice C; Glehen O; Passot G
    Dis Colon Rectum; 2016 Jul; 59(7):615-22. PubMed ID: 27270513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy.
    Shida D; Tsukamoto S; Ochiai H; Kanemitsu Y
    Ann Surg Oncol; 2018 Jan; 25(1):173-178. PubMed ID: 29063295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
    Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M
    World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer.
    Morgan Z; Chow BE; Strong EA; Tsai S; Christians K; Mogal H; Gamblin TC; Clarke CN
    J Surg Res; 2019 Aug; 240():130-135. PubMed ID: 30928770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study.
    Solaini L; D'Acapito F; Passardi A; Framarini M; Tauceri F; Di Pietrantonio D; Frassineti GL; Casadei Gardini A; Cucchetti A; Cavaliere D; Ercolani G
    World J Surg Oncol; 2019 Mar; 17(1):58. PubMed ID: 30917826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
    Klaver YL; Chua TC; Verwaal VJ; de Hingh IH; Morris DL
    J Surg Oncol; 2013 May; 107(6):585-90. PubMed ID: 23280508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. More Synchronous Peritoneal Disease but Longer Survival in Younger Patients with Carcinomatosis from Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Solomon D; DeNicola NL; Feferman Y; Bekhor E; Reppucci ML; Feingold D; Aycart SN; Magge DR; Golas BJ; Labow DM; Sarpel U
    Ann Surg Oncol; 2019 Mar; 26(3):845-851. PubMed ID: 30643994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin.
    Elias D; Mariani A; Cloutier AS; Blot F; Goéré D; Dumont F; Honoré C; Billard V; Dartigues P; Ducreux M
    Eur J Surg Oncol; 2014 Nov; 40(11):1467-73. PubMed ID: 25086990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.
    Frøysnes IS; Larsen SG; Spasojevic M; Dueland S; Flatmark K
    J Surg Oncol; 2016 Aug; 114(2):222-7. PubMed ID: 27173150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of prognostic scores for patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Cashin PH; Graf W; Nygren P; Mahteme H
    Ann Surg Oncol; 2013 Dec; 20(13):4183-9. PubMed ID: 23975316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases.
    van der Werf LR; Wassenaar E; de Niet A; Lalezari F; Braam HJ; van Ramshorst B; Nederend J; de Hingh IHJT; Kok NFM; Aalbers AGJ
    Eur J Surg Oncol; 2019 Mar; 45(3):376-382. PubMed ID: 30414704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients.
    Baratti D; Kusamura S; Iusco D; Bonomi S; Grassi A; Virzì S; Leo E; Deraco M
    Dis Colon Rectum; 2014 Jul; 57(7):858-68. PubMed ID: 24901687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of combined resection of colorectal peritoneal and liver metastases.
    Downs-Canner S; Shuai Y; Ramalingam L; Pingpank JF; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
    J Surg Res; 2017 Nov; 219():194-201. PubMed ID: 29078882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.